Last reviewed · How we verify
DM-101
At a glance
| Generic name | DM-101 |
|---|---|
| Sponsor | Desentum Oy |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Injection Site Erythema
- Rhinorrhoea
- Arthralgia
- Musculoskeletal Pain
- Myalgia
- Headache
- Erythema
- Nasopharyngitis
- Leucocytosis
- Ear Pain
- Conjuctival Hyperaemia
- Eye Pruritus
Key clinical trials
- Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy (PHASE1)
- DCB-DM101 in Healthy Volunteers and for Type 2 Diabetes Mellitus Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DM-101 CI brief — competitive landscape report
- DM-101 updates RSS · CI watch RSS
- Desentum Oy portfolio CI